Valley-Mount Sinai Comprehensive Cancer Care offers PluvictoTM as a treatment option for patients who have been diagnosed with metastatic prostate cancer – prostate cancer that has spread to other parts of the body.

What is Pluvicto?

Pluvicto is an FDA-approved targeted radiogland therapeutic agent developed to treat adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mpCRPC). 

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a treatment option specifically for those with PSMA-positive mpCRPC that has metastasized—spread to other parts of the body—and who have already been treated with other anticancer treatments.

How Pluvicto Works

Pluvicto is delivered through radiogland therapy, an innovative approach where radiation is administered via intravenous (IV) injection or infusion to specifically targeted cancer cells, with a minimal effect on healthy cells. Patients can receive it approximately every six weeks for up to six treatments, depending on how the body responds. It specifically targets PSMA-positive cancer cells. Once the PSMA-positive cells absorb Pluvicto, it releases radiation that can damage and eliminate the cancer cells.

Is Pluvicto Right for You?

Patients considering Pluvicto therapy are encouraged to consult with their urologist or oncologist to determine its suitability for their specific case. A physician referral is required to initiate the Pluvicto treatment.